title: Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
authors.affiliation: Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Pham
authors.forename: R L
authors.initials: RL
authors.lastname: Kormos
authors.forename: A
authors.initials: A
authors.lastname: Kawai
authors.forename: S
authors.initials: S
authors.lastname: Murali
authors.forename: B G
authors.initials: BG
authors.lastname: Hattler
authors.forename: A J
authors.initials: AJ
authors.lastname: Demetris
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003141:Communicable Diseases / Q000453:epidemiology; D003327:Coronary Disease / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus